Table 5

Time to first response (days) in intention-to-treat population, according to initial masitinib dosage

Parameter

3 mg/kg per day

(n = 22)

6 mg/kg per day

(n = 18)

Total population

(n = 40)

P value


ACR20

Patients

12/22 (55.0%)

11/18 (61.0%)

23/40 (57.5%)

0.213

Mean ± SD

51.9 ± 24.5

40.3 ± 19.0

46.3 ± 22.4

Median

56.0

29.0

35.0

Range

28.0–105.0

28.0–86.0

28.0–105.0

ACR50

Patients

7/22 (32.0%)

8/18 (44.0%)

15/40 (37.5%)

0.771

Mean ± SD

91.9 ± 59.5

86.8 ± 61.1

89.1 ± 58.2

Median

84.0

72.5

84.0

Range

28.0–217.0

28.0–203.0

28.0–217.0


ACR20, American College of Rheumatology 20% improvement criteria; ACR50, American College of Rheumatology 50% improvement criteria; SD, standard deviation.

Tebib et al. Arthritis Research & Therapy 2009 11:R95   doi:10.1186/ar2740

Open Data